source
- AstraZeneca attributes Phase 3 failure of bone disease enzyme therapy to trial design flawsAstraZeneca disclosed that its Phase 3 study of an enzyme replacement therapy for a rare genetic bone disorder did not meet its primary objectives. The company said the shortfall was largely due t…
- Biotech closures drop to ten in 2026, marking improvement after years of high layoffsFierce's annual "biotech graveyard" list shows ten company closures reported so far in 2026, a sharp decline from sixteen last year and twenty‑seven in 2023. The drop reflects broader easing of bi…